ABBVAbbVie
Is the business good?
The checks split: 8 of 9 health tests passed and earnings fully cash-backed (1.6×), but margins compressing.
High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.
Operating profit is fully backed by cash. Conversion is worsening vs a year ago.
Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is ABBV?
AbbVie earns 23% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 14 points above what the capital costs: growth creates value
- Operating margin
- 26%
Operating margin · Drug Manufacturers - General median 24% · 12 months to Q2 2026
- Cash conversion
- 1.59×
Cash conversion · 2.23× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- 0.00%
Share count, year on year · flat: no meaningful dilution
| Year | Operating margin |
|---|---|
| FY2020 | 25% |
| FY2021 | 32% |
| FY2022 | 31% |
| FY2023 | 23% |
| FY2024 | 16% |
| FY2025 | 25% |
Details›
- Gross margin12 months to Q2 2026
- 71%
- Operating margin12 months to Q2 2026
- 26%
- Net margin12 months to Q2 2026
- 9.8%
- Free cash flow margin
- 28%
- R&D as % of revenue
- 15%
- Revenue, trailing twelve months
- $64.4B
- Free cash flow, trailing twelve months
- $18.2B
- Net income, trailing twelve months
- $6.31B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 23%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from ABBV and who it buys from, as the companies report it.
- MCKMcKesson Corporation
Named in ABBV’s FY2025 10-K
- IRWDIronwood Pharmaceuticals Inc100%
ABBV is 100% of its revenue · FY2025 10-K
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; ABBV’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported. A link without a share is named in one of the two companies’ annual reports, without a figure.
Drug Manufacturers, General
The closest names by size in the same industry